Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Agentix Corp

Healthcare US AGTX

0.017USD
0.00(0%)

Last update at 2026-06-22T20:00:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.020.06
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap1.76M
  • Volume40700
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.31811M
  • Revenue TTM-0.00124M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.08475M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-08-31 2023-03-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-08-31 2023-03-31 2022-08-31
Income before tax -0.56705M -0.58515M -1.37380M -1.37380M -
Minority interest - - - - -
Net income -0.56705M -0.58515M -1.37421M -1.37421M -
Selling general administrative 0.33M 0.57M 0.66M 0.66M -
Selling and marketing expenses - - - - -
Gross profit - 0.00000M 0.00000M 0.00000M -
Reconciled depreciation - - - - -
Ebit -1.03763M - -1.37176M -1.37176M -2.62663M
Ebitda -0.51325M - -1.37176M -1.37176M -
Depreciation and amortization 0.51M - - 0.02M -
Non operating income net other - - - - -
Operating income -0.51325M -0.74481M -1.37176M -1.37176M -
Other operating expenses 0.51M - 1.37M 1.37M -
Interest expense 0.04M 0.02M 0.00164M 0.00164M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -
Interest income 0.00000M 0.00025M - 0.00000M -
Net interest income -0.04267M -0.02079M -0.00164M -0.00164M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00041M 0.00041M -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 0.51M 0.74M 1.37M 1.37M -
Cost of revenue - 0.00000M 0.00000M 0.00000M -
Total other income expense net -0.05380M 0.18M -0.00205M -0.00205M -
Discontinued operations - - - - -
Net income from continuing ops -0.56705M -0.58515M -1.37380M -1.37380M -
Net income applicable to common shares - - -1.37380M -1.37380M -2.62663M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-08-31 2023-03-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-08-31 2023-03-31 2022-08-31
Total assets 0.10M 0.11M 0.26M 0.26M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.10M - 0.25M 0.25M 0.02M
Total liab 3.20M 2.67M 2.51M 2.51M -
Total stockholder equity -3.10425M -2.56022M -2.24916M -2.24916M -
Deferred long term liab - - - - -
Other current liab 1.62M - 1.45M -0.99811M 0.51M
Common stock 0.04M - 0.04M 0.04M 0.04M
Capital stock 0.04M 0.04M 0.04M 0.04M -
Retained earnings -6.52153M -5.95448M -5.36933M -5.36933M -3.99552M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.00448M 0.00654M 0.01M 0.01M -
Cash and equivalents - - - - -
Total current liabilities 3.20M 2.67M 2.51M 2.51M 1.09M
Current deferred revenue - - -1.44423M -1.44423M -
Net debt 0.24M 0.14M 0.04M 0.04M -
Short term debt 0.24M - 0.05M 0.05M -
Short long term debt 0.24M 0.14M 0.05M 0.05M -
Short long term debt total 0.24M - 0.05M 0.05M -
Other stockholder equity 3.29M - 3.08M 3.08M -
Property plant equipment - - - - -
Total current assets 0.10M 0.11M 0.26M 0.26M 0.02M
Long term investments - - - - -
Net tangible assets - - -2.24916M -2.24916M -1.07700M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.34M 2.50M 2.45M 2.45M 0.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.09M - 0.00076M 0.00076M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-08-31 2023-03-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-08-31 2023-03-31 2022-08-31
Investments 0.00000M 0.00000M 0.00000M 0.00000M -
Change to liabilities - - 1.37M 1.37M 0.80M
Total cashflows from investing activities - - - - -
Net borrowings 0.10M - - - -
Total cash from financing activities 0.10M 0.09M 0.10M 0.10M -
Change to operating activities - - -0.22114M -0.22114M 0.03M
Net income -0.56705M -0.58515M -1.37380M -1.37380M -3.92788M
Change in cash -0.00206M -0.00583M 0.01M 0.01M -0.02520M
Begin period cash flow 0.00654M 0.01M 0.00015M 0.00015M 0.00177M
End period cash flow 0.00448M 0.00654M 0.01M 0.01M 0.00015M
Total cash from operating activities -0.12508M -0.11043M -0.08854M -0.08854M -0.02520M
Issuance of capital stock - 0.00000M 0.05M 0.05M -
Depreciation - - 0.02M 0.02M -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities - - 0.05M 0.05M -
Change to netincome - - - - 1.77M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.44M 0.18M 1.15M 1.15M -
Stock based compensation - - - - -
Other non cash items - 0.29M 0.12M 0.12M -
Free cash flow -0.12508M -0.11043M -0.08854M -0.08854M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGTX
Agentix Corp		 - -% 0.02 - - 2147.54 3587.45 2261.30 -1.3897
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.

Agentix Corp

32932 Pacific Coast Highway, Dana Point, CA, United States, 92629

Key Executives

Name Title Year Born
Mr. Rudy A. Mazzocchi B.Sc. Pres, CEO, Chairman, Principal Accounting Officer 1959
Mr. Salman Hoda Sr. VP Portfolio & Bus. Devel., Sec., Treasurer and Director 1981
Martin Schroeder Chief Scientific Officer & Member of Scientific Advisory Board NA
Mr. David Fiene Controller NA
Mr. Riazul Huda CEO, CFO & Director 1969
Mr. Martin Schroeder Chief Scientific Officer & Member of Scientific Advisory Board 1953
Mr. David Fiene Financial Controller NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.